Aurobindo to acquire under development product, related assets from Advent for $ 12.5 mn

PTI New Delhi | Updated on November 13, 2018 Published on November 13, 2018

Aurobindo Pharma said on Monday its arm Aurobindo Pharma USA Inc has signed a pact to acquire an under-development product and certain related assets from Australian Advent Pharmaceuticals Pty Ltd for $ 12.5 million.

The company’s wholly owned subsidiary, Aurobindo Pharma USA Inc, has entered into an agreement to acquire a product under development and related assets from Advent Pharmaceuticals Pty Ltd, Australia, through its subsidiary AuroScience Pty Ltd Melbourne, Aurobindo Pharma said in a filing to BSE.

The acquisition is for a cash consideration of $ 12.5 million, it added. The indicative time period for completion of the acquisition is January 2019, Aurobindo Pharma said.

The acquisition provides an opportunity to acquire assets that would be used for speciality generics business, it added.


Published on November 13, 2018
This article is closed for comments.
Please Email the Editor